RANKL Inhibition as Therapy for Joint Damage

Japanese Journal of Clinical Immunology
doi 10.2177/jsci.30.404
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Japan Society for Clinical Immunology

Related search

Clinical Development of Anti-Rankl Therapy

Arthritis Research and Therapy
RheumatologyAllergyImmunology
2007English

Fyn Kinase Inhibition as a Novel Therapy for Alzheimer’s Disease

Alzheimer's Research and Therapy
NeurologyCognitive Neuroscience
2014English

Assessing the Role of Daptomycin as Antibiotic Therapy for Staphylococcal Prosthetic Joint Infection

Journal of Bone and Joint Infection
2020English

Filamin-A as a Marker and Target for DNA Damage Based Cancer Therapy

DNA Repair
BiochemistryCell BiologyMolecular Biology
2012English

Plasma Citrulline Level as a Biomarker for Cancer Therapy-Induced Small Bowel Mucosal Damage.

Acta Biochimica Polonica
BiochemistryGeneticsMolecular Biology
2014English

Inhibition of USP14 Deubiquitinating Activity as a Potential Therapy for Tumors With P53 Deficiency

Molecular Therapy - Oncolytics
Cancer ResearchOncologyMolecular MedicinePharmacology
2020English

CDK4/6 Inhibition as Maintenance and Combination Therapy for High Grade Serous Ovarian Cancer

Oncotarget
Oncology
2018English

Habitual Joint Cracking and Radiological Damage.

BMJ
1989English

Inhibition of Cytochrome Bc 1 as a Strategy for Single-Dose, Multi-Stage Antimalarial Therapy

American Journal of Tropical Medicine and Hygiene
MedicineVirologyParasitologyInfectious Diseases
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy